Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM. Bronowicki JP, et al. Among authors: desmorat h. Gastroenterology. 2006 Oct;131(4):1040-8. doi: 10.1053/j.gastro.2006.07.022. Epub 2006 Jul 24. Gastroenterology. 2006. PMID: 17030174 Clinical Trial.
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group. de Lédinghen V, et al. Among authors: desmorat h. J Hepatol. 2002 May;36(5):672-80. doi: 10.1016/s0168-8278(02)00026-0. J Hepatol. 2002. PMID: 11983451 Clinical Trial.
Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
Nicot F, Alric L, Barange K, Métivier S, Dramard JM, Combis JM, Castan B, Meurisse JJ, Payen JL, Garipuy D, Desmorat H, Peron JM, Thebault S, Morin T, Renou C, Barel P, Guerin B, Imbert Y, Sire S, Sauné K, Chatelut E, Izopet J. Nicot F, et al. Among authors: desmorat h. J Med Virol. 2011 Mar;83(3):437-44. doi: 10.1002/jmv.21976. J Med Virol. 2011. PMID: 21264864 Clinical Trial.
Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection.
Fontanges T, Beorchia S, Douvin C, Delassalle P, Combis JM, Hanslik B, Jacques JP, Filoche B, Desmorat H, Chandelier C, Ouzan D. Fontanges T, et al. Among authors: desmorat h. Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):566-72. doi: 10.1016/s0399-8320(07)89432-2. Gastroenterol Clin Biol. 2007. PMID: 17646782 Free article. Clinical Trial.
[Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences].
Roudot-Thoraval F, Abergel A, Allaert F, Bourlière M, Desmorat H, Fagnani F, Fontanges T, Hanana A, Pol S, Zarski JP, Rousseaux C, Gandossi C, Samelson L, Dole S, Dantin S, Eberlé F, Saint-Marc-Girardin MF; Groupe d'Etude Pour Hépavir. Roudot-Thoraval F, et al. Among authors: desmorat h. Gastroenterol Clin Biol. 2001 Dec;25(12):1061-6. Gastroenterol Clin Biol. 2001. PMID: 11910986 Free article. French.
Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial.
Alric L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, Desmorat H, Bureau C, Chaouche N, Dalbergue B, Vinel JP. Alric L, et al. Among authors: desmorat h. J Hepatol. 2001 Aug;35(2):272-8. doi: 10.1016/s0168-8278(01)00110-6. J Hepatol. 2001. PMID: 11580151 Clinical Trial.
24 results